Hopkinson C. Craig's most recent trade in Alkermes plc was a trade of 83,037 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 83,037 | 83,037 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 38,568 | 38,568 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.72 per share. | 02 Mar 2026 | 9,000 | 89,389 (0%) | 0% | 29.7 | 267,485 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 02 Mar 2026 | 5,000 | 98,389 (0%) | 0% | 19.3 | 96,700 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 5,000 | 21,356 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2026 | 6,866 | 13,732 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2026 | 6,866 | 96,438 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.73 per share. | 26 Feb 2026 | 3,049 | 93,389 (0%) | 0% | 30.7 | 93,696 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2026 | 7,689 | 7,690 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2026 | 7,689 | 92,986 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.19 per share. | 23 Feb 2026 | 3,414 | 89,572 (0%) | 0% | 32.2 | 109,897 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 8,897 | 84,535 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 8,897 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 7,673 | 23,019 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 7,673 | 88,704 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.02 per share. | 18 Feb 2026 | 3,504 | 81,031 (0%) | 0% | 32.0 | 112,198 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.00 per share. | 18 Feb 2026 | 3,407 | 85,297 (0%) | 0% | 32 | 109,024 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 25,352 | 83,092 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.55 per share. | 05 Feb 2026 | 7,454 | 75,638 (0%) | 0% | 33.6 | 250,082 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2026 | 5,000 | 26,356 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 02 Feb 2026 | 5,000 | 66,740 (0%) | 0% | 19.3 | 96,700 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.24 per share. | 02 Feb 2026 | 5,000 | 61,740 (0%) | 0% | 34.2 | 171,225 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 02 Feb 2026 | 4,000 | 57,740 (0%) | 0% | 33.5 | 134,160 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 08 Jan 2026 | 5,000 | 66,740 (0%) | 0% | 19.3 | 96,700 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 08 Jan 2026 | 5,000 | 61,740 (0%) | 0% | 30.0 | 150,005 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2026 | 5,000 | 31,356 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 02 Jan 2026 | 4,000 | 61,740 (0%) | 0% | 28 | 112,000 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 03 Dec 2025 | 3,748 | 65,740 (0%) | 0% | 30.0 | 112,447 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 03 Dec 2025 | 3,748 | 69,488 (0%) | 0% | 19.3 | 72,486 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 3,748 | 36,356 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.30 per share. | 01 Dec 2025 | 4,000 | 65,740 (0%) | 0% | 29.3 | 117,200 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.38 per share. | 03 Nov 2025 | 9,000 | 69,740 (0%) | 0% | 30.4 | 273,442 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 03 Nov 2025 | 5,000 | 78,740 (0%) | 0% | 19.3 | 96,700 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 5,000 | 40,104 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.53 per share. | 15 Oct 2025 | 9,000 | 73,740 (0%) | 0% | 31.5 | 283,776 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2025 | 5,000 | 45,104 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 15 Oct 2025 | 5,000 | 82,740 (0%) | 0% | 19.3 | 96,700 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 6,866 | 80,789 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 6,866 | 20,598 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.80 per share. | 26 Feb 2025 | 3,049 | 77,740 (0%) | 0% | 34.8 | 106,090 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 12,279 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 12,279 | 75,100 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,689 | 15,379 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,689 | 77,337 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 5,452 | 69,648 (0%) | 0% | 35.3 | 192,565 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 3,414 | 73,923 (0%) | 0% | 35.3 | 120,582 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 63,991 | 63,991 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 30,692 | 30,692 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 8,896 | 66,771 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 8,896 | 8,897 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.90 per share. | 18 Feb 2025 | 3,950 | 62,821 (0%) | 0% | 35.9 | 141,805 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.69 per share. | 12 Feb 2025 | 171,813 | 90,983 (0%) | 0% | 32.7 | 5,616,808 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 12 Feb 2025 | 111,630 | 262,796 (0%) | 0% | 19.3 | 2,158,924 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 111,630 | 50,104 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 108,833 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.02 per share. | 12 Feb 2025 | 108,833 | 57,875 (0%) | 0% | 36.0 | 3,920,001 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.93 per share. | 12 Feb 2025 | 108,833 | 166,708 (0%) | 0% | 31.9 | 3,475,038 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 87,566 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.03 per share. | 12 Feb 2025 | 87,566 | 151,166 (0%) | 0% | 20.0 | 1,753,947 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.02 per share. | 12 Feb 2025 | 35,586 | 166,708 (0%) | 0% | 34.0 | 1,210,696 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.59 per share. | 12 Feb 2025 | 35,586 | 202,294 (0%) | 0% | 24.6 | 875,060 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 35,586 | 71,172 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.27 per share. | 12 Feb 2025 | 33,108 | 57,875 (0%) | 0% | 33.3 | 1,101,470 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 34,393 | 78,683 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.39 per share. | 06 Feb 2025 | 15,083 | 63,600 (0%) | 0% | 31.4 | 473,455 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.05 per share. | 30 Jan 2025 | 100,918 | 44,290 (0%) | 0% | 32.0 | 3,234,382 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.03 per share. | 30 Jan 2025 | 29,156 | 76,732 (0%) | 0% | 20.0 | 583,995 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 29,156 | 87,566 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 30 Jan 2025 | 26,589 | 103,321 (0%) | 0% | 19.3 | 514,231 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 26,589 | 161,734 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.59 per share. | 30 Jan 2025 | 23,542 | 126,863 (0%) | 0% | 24.6 | 578,898 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 23,542 | 106,758 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.82 per share. | 30 Jan 2025 | 18,345 | 145,208 (0%) | 0% | 26.8 | 492,013 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 18,345 | 92,271 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.07 per share. | 09 Dec 2024 | 61,151 | 47,576 (0%) | 0% | 32.1 | 1,961,406 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.03 per share. | 09 Dec 2024 | 12,452 | 72,182 (0%) | 0% | 20.0 | 249,414 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 12,452 | 116,722 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 12,411 | 110,616 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.82 per share. | 09 Dec 2024 | 12,411 | 108,727 (0%) | 0% | 26.8 | 332,863 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 12,090 | 188,323 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 09 Dec 2024 | 12,090 | 84,272 (0%) | 0% | 19.3 | 233,821 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 12,044 | 130,300 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.59 per share. | 09 Dec 2024 | 12,044 | 96,316 (0%) | 0% | 24.6 | 296,162 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.50 per share. | 05 Dec 2024 | 9,221 | 59,730 (0%) | 0% | 31.5 | 290,462 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.77 per share. | 04 Dec 2024 | 14,349 | 68,951 (0%) | 0% | 30.8 | 441,550 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.08 per share. | 11 Nov 2024 | 58,996 | 83,300 (0%) | 0% | 30.1 | 1,774,576 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.03 per share. | 11 Nov 2024 | 43,058 | 142,296 (0%) | 0% | 20.0 | 862,452 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 43,058 | 129,174 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.53 per share. | 06 Nov 2024 | 10,471 | 99,238 (0%) | 0% | 29.5 | 309,169 | Ordinary Shares |
| Alkermes PLC | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 111,186 | 111,186 | - | - | Employee Stock Option (Right to Buy) | |
| Alkermes PLC | Craig Hopkinson C. | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 27,464 | 27,464 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,689 | 23,068 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,689 | 113,123 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.57 per share. | 23 Feb 2024 | 3,414 | 109,709 (0%) | 0% | 29.6 | 100,952 | Ordinary Shares |
| Alkermes PLC | Craig Hopkinson C. | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 12,278 | 12,279 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 12,278 | 110,886 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 22 Feb 2024 | 5,452 | 105,434 (0%) | 0% | 28.9 | 157,617 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 10,297 | 103,180 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 10,297 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes PLC | Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 8,897 | 96,834 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 8,897 | 17,793 | - | - | Restricted Stock Unit Award |